Oesophageal cancer metastases: An observational study of a more aggressive approach

Table 1 Clinical characteristics of patients

Patient	Age in yr	Sex	Primary tumour location	Histologic type of tumour	Differentiation	Clinical stage of primary tumour	Neoadjuvant therapy	Oesophagectomy	ypTNM
Synchronous and Metachronous Oligometastatic Disease
11	62	Female	Upper third	SCC	Moderate	T4N1M1	Walsh Regimen17	No	NA
22	53	Male	OGJ	AC	Poor	T3N2M1	Walsh Regimen + CROSS	Yes	T2bN1Mx
Synchronous Oligometastatic Disease Only
3	71	Male	Lower third/OGJ	AC	Poor	T3N1M1	Carbo5FU; 60Gy	Yes	T3N0M0
4	68	Male	OGJ	AC	Moderate-poor	T3N2M0	Walsh Regimen	Yes	T2N0Mx
Metachronous Oligometastatic Disease Only
5	56	Male	Middle/lower third	SCC	Moderate	T3N2M0	Walsh Regimen	Yes	T2N1Mx
6	36	Male	Lower	AC	Moderate	T3N1M0	CROSS	Yes	T3N0Mx
73	72	Female	OGJ	AC	Moderate	T3N0M0	CROSS	Yes	T2N0
8	70	Male	OGJ	AC	Poor	Nodal disease/Stage IIIA	MAGIC	Yes	T2N1Mx
9	48	Male	Lower third	AC	Poor	Stage IIB	Walsh Regimen	Yes	T1N0Mx
104	57	Male	Lower third	AC	Poor	T3N0M0	CROSS	Yes	T2N0M0
11	60	Male	OGJ	AC	Poor	T3N0M0	CROSS	Yes	T0N0Mx

¹Patient 1 had a complete clinical response.

²Patient 2 received six cycles of cisplatin and fluorouracil, followed by six cycles of paclitaxel and carboplatin.

³Patient 7 underwent salvage surgery after surveillance Positron-emission tomography suggested residual disease despite initial complete clinical response to neoadjuvant chemoradiotherapy.

⁴Patient 10 was diagnosed with a synchronous primary renal cell carcinoma, which was discovered incidentally during staging for his oesophageal cancer. He was referred to a urology service in another hospital and treated with radiofrequency ablation.

ypTNM: Pathologic staging after neoadjuvant therapy; Walsh Regimen¹⁷: Cisplatin/5-fluorouracil, 40 Gy concurrent radiotherapy; CROSS: The Dutch Chemoradiotherapy for Oesophageal Cancer Followed by Surgery study–weekly carboplatin and paclitaxel with concurrent radiotherapy; Carbo5FU: Carboplatin/5-fluorouracil; MAGIC: Epirubicin, cisplatin, and fluorouracil; NA: Not applicable; OGJ: Oesophagogastric junction; AC: Adenocarcinoma; SCC: Squamous cell carcinoma.